Back to Directory
Nesiritide
Performance & EnduranceRecombinant BNP for acute decompensated heart failure, causes vasodilation and diuresis.
Key Benefits
- ✓Vasodilation
- ✓Reduces cardiac preload and afterload
- ✓Promotes diuresis
- ✓Treats acute heart failure
- ✓Reduces pulmonary capillary wedge pressure
Dosing Information
Dosage Range
2 mcg/kg bolus
Frequency
Continuous IV infusion
Typical Duration
Until stabilization
Detailed Protocol
Administered via intravenous infusion in hospital/ICU setting for acute heart failure. Bolus followed by continuous infusion. Medical supervision required.
About Nesiritide
Nesiritide (Natrecor) is recombinant human B-type natriuretic peptide (BNP). It binds to guanylate cyclase receptors, causing vasodilation, natriuresis, and diuresis. FDA-approved for acute decompensated heart failure.
Research Notes
FDA-approved in 2001 for acute heart failure. Use has decreased due to concerns about renal function and mortality. Reserved for specific acute situations.
Potential Side Effects
- •Hypotension (common)
- •Headache
- •Nausea
- •Requires ICU monitoring
- •Potential kidney dysfunction
Always consult with a healthcare professional before starting any peptide therapy.